Regimens used anytime during the first 3 therapy attempts in all patients
| Treatment regimen . | n . |
|---|---|
| AZT-IFN alone | 96 |
| AZT-IFN plus chemotherapy | 17 |
| Concurrent treatment | 9 |
| Sequential: chemotherapy→AZT-IFN | 8 |
| Multiagent chemotherapy regimens | 175 |
| CHOP-like (n): CHOP (42), liposomal doxorubicin–based CHOP (7), CHOP-bleo (1), CHOP-bortezomib (1), CHOP- denileukin diftitox (1), CHOP-fludarabine (1), CNOP-bleo (2) | 55 |
| Etoposide based (n): EPOCH based: DA-EPOCH/bortezomib/raltegravir (4), DA-EPOCH ± sequential AI (29); CEOP-like (3), CDE (1), CHOEP (4), CODOX-IVAC/ICE (1), etoposide/Ara-C/prednisone/cyclophosphamide (1), etoposide/novantrone/cyclophosphamide/prednisone (1), gemcitabine/ cyclophosphamide/vincristine/prednisone/CHOEP (1), mini-BEAM (1), hyper-CVAD/IVAC (1), IVAC (1) | 48 |
| Platinum based (n): VCAP-AP-VECP (V = vincristine, no ranimustine); modified version of Japanese LSG15 regimen (28); DHAP (3), ESHAP (1), gemcitabine/carboplatin (1), GEMOX (2), ICE (6), VECP (3), ProMACE/CytaBOM (3) | 47 |
| MTX based (n): CHOEP/high-dose MTX-AZT (1), CODOX-M/IVAC + AZT (1), CODOX-M/IVAC + brentuximab (1), etoposide/MTX/prednisone (1), high-dose MTX ± AZT (6), hyperCVAD/MTX-ARA-C (7), MACOP-B (2), SMILE (1) | 20 |
| Other combinations (n): doxil/bortezomib (1), pentostatin/cyclophosphamide (2), VACOP-B (2) | 5 |
| Single-agent chemotherapy (n): ARA-C (1), cladribine (2), doxil (1), etoposide (11), pentostatin (1), pralatrexate (7) | 23 |
| Investigational agents (n): alemtuzumab ± AI (8), belinostat ± AZT (3), bortezomib (1), brentuximab vedotin (6), denileukin diftitox (2), mogamulizumab (2), valproic acid/AZT (1), vorinostat-AZT (1) | 24 |
| Allo-HSCT | 5 |
| Treatment regimen . | n . |
|---|---|
| AZT-IFN alone | 96 |
| AZT-IFN plus chemotherapy | 17 |
| Concurrent treatment | 9 |
| Sequential: chemotherapy→AZT-IFN | 8 |
| Multiagent chemotherapy regimens | 175 |
| CHOP-like (n): CHOP (42), liposomal doxorubicin–based CHOP (7), CHOP-bleo (1), CHOP-bortezomib (1), CHOP- denileukin diftitox (1), CHOP-fludarabine (1), CNOP-bleo (2) | 55 |
| Etoposide based (n): EPOCH based: DA-EPOCH/bortezomib/raltegravir (4), DA-EPOCH ± sequential AI (29); CEOP-like (3), CDE (1), CHOEP (4), CODOX-IVAC/ICE (1), etoposide/Ara-C/prednisone/cyclophosphamide (1), etoposide/novantrone/cyclophosphamide/prednisone (1), gemcitabine/ cyclophosphamide/vincristine/prednisone/CHOEP (1), mini-BEAM (1), hyper-CVAD/IVAC (1), IVAC (1) | 48 |
| Platinum based (n): VCAP-AP-VECP (V = vincristine, no ranimustine); modified version of Japanese LSG15 regimen (28); DHAP (3), ESHAP (1), gemcitabine/carboplatin (1), GEMOX (2), ICE (6), VECP (3), ProMACE/CytaBOM (3) | 47 |
| MTX based (n): CHOEP/high-dose MTX-AZT (1), CODOX-M/IVAC + AZT (1), CODOX-M/IVAC + brentuximab (1), etoposide/MTX/prednisone (1), high-dose MTX ± AZT (6), hyperCVAD/MTX-ARA-C (7), MACOP-B (2), SMILE (1) | 20 |
| Other combinations (n): doxil/bortezomib (1), pentostatin/cyclophosphamide (2), VACOP-B (2) | 5 |
| Single-agent chemotherapy (n): ARA-C (1), cladribine (2), doxil (1), etoposide (11), pentostatin (1), pralatrexate (7) | 23 |
| Investigational agents (n): alemtuzumab ± AI (8), belinostat ± AZT (3), bortezomib (1), brentuximab vedotin (6), denileukin diftitox (2), mogamulizumab (2), valproic acid/AZT (1), vorinostat-AZT (1) | 24 |
| Allo-HSCT | 5 |
AP, doxorubicin, prednisone; BEAM, carmustine, etoposide, cytarabine, melphalan; Bleo, bleomycin; CDE, cyclophosphamide, doxorubicin, etoposide; CHOEP, etoposide, cyclophosphamide, vincristine, doxorubicin and prednisone; CNOP, cyclophosphamide, novantrone, vincristine, and prednisone; CODOX-M, cyclophosphamide, vincristine and doxorubicin-methotrexate/ifosfamide; DA-EPOCH, dose-adjusted etoposide, cyclophosphamide, vincristine, doxorubicin and prednisone; DHAP, dexamethasone, high-dose cytarabine and cisplatin; ESHAP, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin; GEMOX, gemcitabine, oxaliplatin; ICE, ifosfamide, carboplatin and etoposide; hyper-CVAD, cyclophosphamide, vincristine, doxorubicin and dexamethasone, alternated with high-dose cytarabine and methotrexate; IVAC, ifosfamide, etoposide and cytarabine; MACOP-B, methotrexate, doxorubicin, cyclophosphamide, prednisone, bleomycin; MTX, methotrexate; ProMACE/CytaBOM, prednisone, doxorubicin, cyclophosphamide, etoposide, cytarabine, bleomycin, vincristine, methotrexate, and leucovorin; SMILE, dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide; VCAP-AP-VECP→VCAP, vincristine, cyclophosphamide, doxorubicin and prednisone; VACOP-B, vincristine, doxorubicin, cyclophosphamide, prednisone, bleomycin; VECP, vincristine, etoposide, carboplatin, and prednisone.